The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy

Acta Histochemica

Volumn 113, Issue 8, 2011, Pages 826-832

  Tunçdemir, Matem ^a   Öztürk, Melek ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Diabetic nephropathy; Microalbuminuria; Podocytes; Rat; STZ diabetes; WT 1

Indexed keywords

CASPASE 3; GLUCOSE; IRBESARTAN; MESSENGER RNA; PROTEIN BAX; TRANSFORMING GROWTH FACTOR BETA1; WT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAX GENE; CASPASE 3 GENE; CELL COUNT; CELL DAMAGE; CELL PROTECTION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE MARKER; DRUG EFFECT; DRUG MECHANISM; GENE; GENE EXPRESSION REGULATION; GLOMERULAR DYSFUNCTION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY BLOOD FLOW; KIDNEY INJURY; KIDNEY MASS; KIDNEY STRUCTURE; MALE; MICROALBUMINURIA; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; TRANSFORMING GROWTH FACTOR BETA1 GENE; TUMOR SUPPRESSOR GENE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIPHENYL COMPOUNDS; CASPASE 3; DIABETIC NEPHROPATHIES; KIDNEY GLOMERULUS; MALE; PODOCYTES; RATS; RATS, WISTAR; STREPTOZOCIN; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1; WT1 PROTEINS;

RATTUS;

EID: 80054939135     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2010.12.003     Document Type: Article

References (38)

1. Bonnet F., Cooper M.E., Kawachi H., Allen T.J., Boner G., Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001, 44:874-877.
2. Böttinger E.P. TGF-beta in renal injury and disease. Semin Nephrol 2007, 27:309-320.
3. Ding G., Reddy K., Kapasi A.A., Franki N., Gibbons N., Kasinath B.S., et al. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol 2002, 283:F173-F180.
4. Fukuzawa R., Eccles M.R., Ikeda M., Hata J. Embryonal hyperplasia of Bowman's capsular epithelium in patients with WT1 mutations. Pediatr Nephrol 2003, 18:9-13.
5. Gilbert R.E., Cox A., Wu L.L., Allen T.J., Hulthen U.L., Jerums G., et al. Expression of transforming growth factor-ß1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 1998, 47:414-422.
6. Gross M.L., El-Shakmak A., Szábó A., Koch A., Kuhlmann A., Münter K., et al. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003, 46:856-868.
7. Guo J.K., Menke A.L., Gubler M.C., Clarke A.R., Harrison D., Hammes A., et al. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet 2002, 11:651-659.
8. Jia J., Ding G., Zhu J., Chen C., Liang W., Franki N., et al. Angiotensin II infusion induces nephrin expression changes and podocyte apoptosis. Am J Nephrol 2008, 28:500-507.
9. Kalender B., Oztürk M., Tunçdemir M., Uysal O., Dagistanli F.K., Yegenaga I., et al. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats. Acta Histochem 2002, 104:123-130.
10. Kelly D.J., Cox A.J., Tolcos M., Cooper M.E., Wilkinson-Berka J.L., Gilbert R.E. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int 2002, 61:31-39.
11. Kim Y.H., Goyal M., Kurnit D., Wharram B., Wiggins J., Holzman L., et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001, 60:957-968.
12. Kriz W., LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 2005, 67:404-419.
13. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
14. Li Y., Kang Y.S., Dai C., Kiss L.P., Wen X., Liu Y. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 2008, 172:299-308.
15. Liebau M.C., Lang D., Böhm J., Endlich N., Bek M.J., Witherden I., et al. Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006, 290:F710-F719.
16. Liu B.C., Chen Q., Luo D.D., Sun J., Philips A.O., Ruan X.Z., et al. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 2003, 24:67-73.
17. Macconi D., Sangalli F., Bonomelli M., Conti S., Condorelli L., Gagliardini E., et al. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Am J Pathol 2009, 174:797-807.
18. Menini S., Iacobini C., Oddi G., Ricci C., Simonelli P., Fallucca S., et al. Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease. Diabetologia 2007, 50:2591-2599.
19. Meyer T.W., Bennett P.H., Nelson R.G. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999, 42:1341-1344.
20. Mifsud S.A., Allen T.J., Bertram J.F., Hulthen U.L., Kelly D.J., Cooper M.E., et al. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001, 44:878-882.
21. Mundlos S., Pelletier J., Darveau A., Bachmann M., Winterpacht A., Zabel B. Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. Development 1993, 119:1329-1341.
22. Nagata M., Tomari S., Kanemoto K., Usui J., Lemley K.V. Podocytes, parietal cells, and glomerular pathology: the role of cell cycle proteins. Pediat Nephrol 2003, 18:3-8.
23. Ortiz A., Justo P., Sanz A., Lorz C., Egido J. Targeting apoptosis in acute tubular injury. Biochem Pharmacol 2003, 66:1589-1594.
24. Pagtalunan M.E., Miller P.L., Jumping-Eagle S., Nelson R.G., Myers B.D., Rennke H.G., et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997, 99:342-348.
25. Palmer R.E., Kotsianti A., Cadman B., Boyd T., Gerald W., Haber D.A. WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Curr Biol 2001, 11:1805-1809.
26. Patek C.E., Fleming S., Miles C.G., Bellamy C.O., Ladomery M., Spraggon L., et al. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis. Hum Mol Genet 2003, 12:2379-2394.
27. Petermann A.T., Pippin J., Krofft R., Blonski M., Griffin S., Durvasula R., et al. Viable podocytes detach in experimental diabetic nephropathy: potential mechanism underlying glomerulosclerosis. Nephron Exp Nephrol 2004, 98:114-123.
28. Petermann A.T., Krofft R., Blonski M., Hiromura K., Vaughn M., Pichler R., et al. Podocytes that detach in experimental membranous nephropathy are viable. Kidney Int 2003, 64:1222-1231.
29. Reddy G.R., Kotlyarevska K., Ransom R.F., Menon R.K. The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy?. Curr Opin Nephrol Hypertens 2008, 17:32-36.
30. Siu B., Saha J., Smoyer W.E., Sullivan K.A., Brosius F.C. Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment. BMC Nephrol 2006, 7:6.
31. Sohn E., Kim J., Kim C.S., Kim Y.S., Jang D.S., Kim J.S. Extract of the aerial parts of Aster koraiensis reduced development of diabetic nephropathy via anti-apoptosis of podocytes in streptozotocin-induced diabetic rats. Biochem Biophys Res Commun 2010, 391:733-738.
32. Stitt-Cavanagh E., MacLeod L., Kennedy C. The podocyte in diabetic kidney disease. Sci World J 2009, 9:1127-1139.
33. Susztak K., Raff A.C., Schiffer M., Böttinger E.P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006, 55:225-233.
34. Tunçdemir M., Ozturk M. The effects of ACE inhibitor and angiotensin receptor blocker on clusterin and apoptosis in the kidney tissue of streptozotocin-diabetic rats. J Mol Histol 2008, 39:605-616.
35. Wagner K.D., Wagner N., Schedl A. The complex life of WT1. J Cell Sci 2003, 116:1653-1658.
36. White K.E., Bilous R.W., Marshall S.M., El Nahas M., Remuzzi G., Piras G., et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002, 51:3083-3089.
37. Yang B., Johnson T.S., Thomas G.L., Watson P.F., Wagner B., Skill N.J., et al. Expression of apoptosis-related genes and proteins in experimental chronic renal scarring. J Am Soc Nephrol 2001, 12:275-288.
38. Yang B., Johnson T.S., Thomas G.L., Watson P.F., Wagner B., Furness P.N., et al. A shift in the Bax/Bcl-2 balance may activate capsase-3 and modulate apoptosis in experimental glomerulonephritis. Kidney Int 2002, 62:1301-1313.